1-4 of 4
Subba R. Digumarthy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes

Catherine B. Meador, Subba R. Digumarthy, Beow Y. Yeap, Yin P. Hung, Mari Mino-Kenudson, Anna F. Farago, Rebecca S. Heist, J. Paul Marcoux, Deepa Rangachari, David A. Barbie, Zofia Piotrowska
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 25–34.
https://doi.org/10.1158/1078-0432.CCR-24-2350
Published: 06 January 2025
View article titled, Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
Open the PDF for Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes in another window
Includes: Supplementary data
Journal Articles

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

Joshua K. Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, Matthew R. Strickland, Rebecca S. Heist, Mohini Singh, Naema Nayyar, Anita Giobbie-Hurder, Subba R. Digumarthy, Justin F. Gainor, Anant P. Rajan, Edwin Nieblas-Bedolla, Aaron C. Burns, Jill Hallin, Peter Olson, James G. Christensen, Sylvia C. Kurz, Priscilla K. Brastianos, Hiroaki Wakimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3318–3328.
https://doi.org/10.1158/1078-0432.CCR-22-0383
Published: 02 August 2022
View article titled, Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS<sup>G12C</sup>-Mutant Non–Small Cell Lung Cancer
Open the PDF for Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS<sup>G12C</sup>-Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

Jessica J. Lin, Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, Ted W. Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Charlotte Lee, Andrew Do, Jennifer Peterson, Kylie Prutisto-Chang, Wafa Malik, Harper G. Hubbeling, Adam Langenbucher, Adam J. Schoenfeld, Christina J. Falcon, Jennifer S. Temel, Lecia V. Sequist, Beow Y. Yeap, Jochen K. Lennerz, Alice T. Shaw, Michael S. Lawrence, Sai-Hong Ignatius Ou, Aaron N. Hata, Alexander Drilon, Justin F. Gainor
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2899–2909.
https://doi.org/10.1158/1078-0432.CCR-21-0032
Published: 15 May 2021
View article titled, Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <em>ROS1</em> Fusion–Positive Lung Cancer
Open the PDF for Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <em>ROS1</em> Fusion–Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K. Lennerz, Adam Langenbucher, Jessica J. Lin, Marguerite M. Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A. Adams, Beow Y. Yeap, Emily Chin, Andrew Do, Hetal D. Marble, Sara E. Stevens, Subba R. Digumarthy, Ashish Saxena, Rebecca J. Nagy, Cyril H. Benes, Christopher G. Azzoli, Michael S. Lawrence, Justin F. Gainor, Alice T. Shaw, Aaron N. Hata
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2535–2545.
https://doi.org/10.1158/1078-0432.CCR-19-3906
Published: 01 June 2020
View article titled, MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Open the PDF for MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer in another window
Includes: Supplementary data